BI 1569912

DRUG5 trials

Sponsors

Boehringer Ingelheim

Conditions

Depressive Disorder, MajorHealthy

Phase 1

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

TerminatedNCT04445090

Boehringer IngelheimHealthy

Start: 2020-07-21End: 2021-09-10Updated: 2026-05-22

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

CompletedNCT04958252

Boehringer IngelheimHealthy

Start: 2021-08-05End: 2023-10-30Updated: 2026-05-22

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

CompletedNCT04978506

Boehringer IngelheimHealthy

Start: 2021-09-03End: 2024-07-04Updated: 2026-06-26

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

CompletedNCT06367153

Boehringer IngelheimHealthy

Start: 2024-05-15End: 2024-08-20Updated: 2026-05-22

Phase 2

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

CompletedNCT06280235

Boehringer IngelheimDepressive Disorder, Major

Start: 2024-03-27End: 2025-03-28Updated: 2026-03-27

Related Papers

Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials

Journal of Psychopharmacology2026-09-02